Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.
Mehrdad Mobasher
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Jane Huang
Employment or Leadership Position - Genentech
Rebecca L. Elstrom
Employment or Leadership Position - Genentech
Mostafa Elhamy
Employment or Leadership Position - Genentech
Coen Bernaards
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Michael J. Hallek
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Peter Hillmen
Honoraria - Roche
Research Funding - Roche
Arnon Philip Kater
Honoraria - Roche Netherlands
Thomas J. Kipps
Consultant or Advisory Role - AbbVie; Celgene; Genentech; Panacea Pharmaceuticals
Research Funding - AbbVie; Genentech
John Francis Seymour
Consultant or Advisory Role - AbbVie; Genentech; Roche
Honoraria - AbbVie; Genentech; Roche
Research Funding - AbbVie; Roche
Other Remuneration - Roche